Akebia Therapeutics (AKBA) Receivables (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Receivables of $62.8 million for Q1 2026, little changed year-over-year from $63.1 million in Q1 2025, and up 27.14% quarter-over-quarter from $49.4 million in Q4 2025.
Akebia Therapeutics (AKBA) Receivables (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Receivables for 14 consecutive years, with $62.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables changed 0.42% year-over-year to $62.8 million; the TTM figure through Mar 2026 stood at $62.8 million (changed 0.42% YoY), while the FY2025 annual figure was $49.4 million, up 35.86% from the prior year.
- Receivables grew to $62.8 million in Q1 2026 per AKBA's latest filing, from $49.4 million in the prior quarter.
- Across five years, Receivables topped out at $138.6 million in Q2 2022 and bottomed at $18.7 million in Q1 2023.
- Historically, Receivables has averaged $50.0 million across 5 years, with a median of $41.1 million in 2022.
- Annual changes were most pronounced in 2022 — Receivables jumped 266.53% — and 2023, when it sank 85.5%.
- Akebia Therapeutics' Receivables stood at $41.1 million in 2022, then climbed by 3.79% to $42.6 million in 2023, then declined by 14.65% to $36.4 million in 2024, then jumped by 35.86% to $49.4 million in 2025, then rose by 27.14% to $62.8 million in 2026.
- Business Quant data shows AKBA's Receivables at $62.8 million in Q1 2026, $49.4 million in Q4 2025, and $66.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.08 Bn |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 56.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.33 Mn |
| Mar 31, 2026 | 62.84 Mn |
| Dec 31, 2025 | 49.42 Mn |
| Sep 30, 2025 | 66.72 Mn |
| Jun 30, 2025 | 74.85 Mn |
| Mar 31, 2025 | 63.10 Mn |
| Dec 31, 2024 | 36.38 Mn |
| Sep 30, 2024 | 34.00 Mn |
| Jun 30, 2024 | 31.59 Mn |
| Mar 31, 2024 | 29.31 Mn |
| Dec 31, 2023 | 42.62 Mn |
| Sep 30, 2023 | 22.59 Mn |
| Jun 30, 2023 | 20.10 Mn |
| Mar 31, 2023 | 18.73 Mn |
| Dec 31, 2022 | 41.07 Mn |
| Sep 30, 2022 | 28.88 Mn |
| Jun 30, 2022 | 138.63 Mn |
| Mar 31, 2022 | 89.67 Mn |
| Dec 31, 2021 | 19.79 Mn |
| Sep 30, 2021 | 71.10 Mn |